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Structural and molecular dissection of the juxtaglomerular ap-
paratus: New aspects for the role of nitric oxide. The juxtaglo-
merular apparatus (JGA) is composed of the macula densa (MD),
the extraglomerular mesangium, and the juxtaglomerular arte-
rioles. The JGA functions to adapt glomerular filtration rate
(GFR) to distal tubular [NaCl] and to adjust the synthesis and
release of renin. The type 1 isoform of nitric oxide synthase
(NOS1) is present in MD cells, and release of NO toward the
glomerular vasculature is thought to modulate signaling at the
JGA. Chronic alterations in GFR and/or tubular [NaCl] are
paralleled by adjustments of NOS1. Molecular characterization of
NOS1 mRNA reveals several renal variants suggesting cell type-
specific regulation at the level of transcription and translation.
The juxtaglomerular apparatus (JGA) is a complex as-
sembly of specialized structures related to each other
anatomically, forming the vascular pole of the glomerulus.
The JGA comprises: the macula densa (MD), an epithelial
cell plaque belonging to the end portion of the thick
ascending limb (TAL), the extraglomerular mesangium
(EGM), which is directly attached to the MD, fills the
angles between the glomerular arteriole, and is in continu-
ity with the intraglomerular mesangium, and the juxtaglo-
merular portions of the afferent and efferent arterioles with
renin-producing cells present in the wall of the terminal
afferent arteriole.
Macula densa
The MD is a plaque of 20 to 30 cells that are different
from TAL cells: they are taller and do not interdigitate, and
the nuclei are large and narrowly packed. MD cells selec-
tively express nitric oxide synthase type 1 (NOS1; see later
here) and stain preferentially for glucose-6-phosphate de-
hydrogenase, which mediates the formation of nicotin-
amide adenine dinucleotide phosphate (NADPH), a cosub-
strate for NOS, by reduction of NADP1 [1]. They express
b-6 integrin, a fibronectin receptor that may be involved in
interactions with the EGM [2]. MD cells can detect changes
in luminal [NaCl], and they possess an apical furosemide-/
bumetanide-sensitive Na1-2Cl2-K1 cotransporter (NKCC2)
like the surrounding TAL cells [3, 4]. The NKCC2 belongs
to the electroneutral Na1-(K1)-Cl2 cotransporter gene
family that also includes the thiazide-sensitive Na1-Cl2
cotransporter (TSC); the cDNAs encoding these cotrans-
porters have been cloned recently [5]. NKCC2 mRNA has
been detected histochemically in rat, rabbit, and mouse
medullary and cortical TAL and in the short post-MD
segment [6]. Significant expression is present also in the
cells of the MD (Fig. 1). The distal tubule expresses TSC
only beyond the MD with an abrupt onset at the transition
between TAL and the distal convoluted tubule [7].
Extraglomerular mesangium
Cells of the EGM (Goormaghtigh cells) are ramified
cells with a scanty cytoplasm; they are surrounded by a
conspicuous matrix and couple to each other and to the
vascular cells by gap junctions. EGM cells are thought to be
contractile smooth muscle-derived cells, and they reveal—
just as the terminal portion of the afferent arteriole—
significant immunoreactivity for soluble guanylate cyclase,
the principal NO “receptor” (S. Bachmann and D.
Koesling, unpublished observations).
Granular cells
The granular cells are modified smooth muscle cells
located in groups (four to five cells) in the terminal portion
of the afferent, and rarely also in the efferent, arteriole.
Within these cells, renin, the pacemaker enzyme of the
renin angiotensin system, is stored in large, lysosomal-type
intracellular granules, and abundant amounts of renin
mRNA are regularly colocalized [8]. Granular cells may
contact the EGM, adjacent smooth muscle cells, and
arteriolar endothelium, and they are coupled to these
structures by gap junctions. They may also lie adjacent to
MD cells [9]. Histochemically, the terminal portion of the
afferent arteriole expresses the angiotensin II (Ang II)
receptor (AT1) [10] and type II cGMP-dependent protein
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kinase, which could be involved in the regulation of renin
release [11].
JUXTAGLOMERULAR APPARATUS: FUNCTIONS
The notion that the cells of the MD are in close contact
with the vascular pole has led to the concept that, in
response to a change in composition of the tubular fluid,
the MD cells release one or several substances that have an
effect on the vascular component of the JGA. The principal
functions of the JGA are as a controller, adapting glomer-
ular filtration rate (GFR) to early distal tubular [NaCl]
(tubuloglomerular feedback, TGF), as reviewed in [12, 13],
and to adjust the regulation of renin synthesis and release.
The latter is one of several mechanisms determining the
production of renin, as reviewed in [13, 14]. Both of these
functions relate to changes in luminal [NaCl] at, and NaCl
transport by, the MD.
Tubuloglomerular feedback
In 1965, Thurau and Schnermann suggested for the first
time that the delivery and reabsorption of NaCl at the MD
determines the TGF response, that is, the modulation of
the afferent arteriolar tone [15]. Increases in flow in the
loop of Henle activate TGF and decrease GFR. The TGF
mechanism serves as a short-term regulator of GFR to
keep distal NaCl delivery constant (J. Schnermann et al,
this issue). Although a flow-dependent increase in [NaCl] is
usually thought to be the initial activating stimulus, it is not
entirely clear whether total tubular fluid concentration or
[Na1] or [Cl2] alone may act as the signal for TGF [4, 16].
It is now widely accepted that the NKCC2 cotransporter in
the MD is essentially involved in the TGF response [4];
loop diuretics such as furosemide inhibit the TGF by
inhibiting NKCC2. The magnitude of the TGF response
varies as a function of the solute concentration bathing the
MD cells. It is not clear, however, whether the rate of
transporter activity is proportionally related to MD sensing.
Regulation of renin secretion
Synthesis and release of renin from juxtaglomerular cells
are controlled by humoral factors, changes in arteriolar
pressure, activity of sympathetic nerves, and by the so-
called MD mechanism [14, 17]. The latter implies chronic
signaling through the MD in response to a change in salt
balance or, more directly, in salt transport: the level of
renin release is inversely related to the luminal salt con-
centration [18, 19]. The crucial role of changes in luminal
[Cl2] on the regulation of renin secretion has been studied
in isolated preparations [19]. Sensing of luminal [Cl2] by
the MD depends on net apical transport, which is mediated
by the NKCC2 [18].
MACULA DENSA SIGNALING
Intracellular signaling
Consequent to activation of the luminal sensing mecha-
nism, an intracellular signal transduction pathway is trig-
gered that finally leads to the release of a vasoactive
stimulus. The stimulus that triggers the TGF response is the
opposite to that stimulating renin secretion, and it is still
unclear whether the same signaling mechanisms are used to
mediate these two different responses. Increases in tubular
fluid solute concentration have been reported to activate
intracellular Ca21 release [20], which, in turn, would acti-
vate a vasoactive messenger, a process that could be
inhibited by elevations in cAMP. However, Salomonsson et
al [21] have reported opposite changes in MD cell Ca21
after changes of luminal [NaCl].
Fig. 1. Histochemical labeling of the juxtaglomerular portion of thick ascending limb (TAL) in rat with in situ hybridization using a Na1-2Cl2-K1
cotransporter (NKCC2) antisense probe (A; digoxigenin-phosphatase labeling) and with nicotinamide adenine dinucleotide phosphate (NADPH)
diaphorase staining indicating nitric oxide synthase type 1 (NOS1) activity (B) on consecutive sections. Diaphorase-positive cells of the macula densa
(MD) are also positive for NKCC2 mRNA (collaboration with N. Obermu¨ller and D. Ellison). Magnification 3300.
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Paracrine candidates for vascular signaling
Initially, Ang II was thought to mediate the TGF re-
sponse; however, this proved untenable for several reasons,
including the inability of the MD to produce Ang II. Later,
a number of other agents such as adenosine, adenosine
triphosphate, and cyclooxygenase pathways have been pro-
posed to transmit tubulovascular signaling, as reviewed in
[12–14, 22]. Particular attention has been paid to NO as a
readily diffusable messenger. Two isoforms of constitutive
NOS have been localized at the vascular pole of the
glomerulus: NOS1 (also termed neuronal NOS) is ex-
pressed selectively in the cells of the MD and a few cells of
the parietal epithelium of Bowman’s capsule; NOS1 immu-
noreactivity and mRNA expression colocalize in MD, and
NADPH diaphorase staining, which indicates activity of the
enzyme-producing NO and citrullin from L-arginine, colo-
calizes as well (Fig. 1, 2) [23, 24]. NOS3 (also termed
endothelial NOS) is found in the endothelia of afferent and
efferent glomerular arterioles. The terminal portion of the
afferent arteriole including the granular cells is thus in
intimate vicinity of two sources of NO, that is, MD and
vascular endothelium (Fig. 3). So far, several studies have
suggested potential roles for MD-derived NO as a mediator
or modulator in tubulovascular signaling [24–26]. In addi-
tion, however, a shear stress-dependent contribution of
endothelium-derived NO released to the juxtaglomerular
cells must be considered as well (Fig. 3).
NOS1 at the MD
Although NOS1 is a constitutive enzyme regulated by
Ca21 and calmodulin, chronic stimulation by diuretics, salt
depletion, or unilateral arterial stenosis increases not only
the activity of MD NOS1 but also the rate of transcription
and translation of the enzyme [19, 26] (see also R. Blantz,
this issue). In addition, changes in the rate of NOS1
synthesis are paralleled by changes in renin synthesis and
release [19, 26, 27]. Together with results obtained from
specific blockers of NO production, there are now several
lines of evidence that NOS1 is involved in the modulation
of renin release. This is the rationale for analysis of
potential regulatory elements of NOS1.
NOS1 was originally isolated from brain, and two alter-
native first exons (591 and 592) have been identified in
humans. Based on further data suggesting tissue-specific
regulation of NOS1, we anticipated that a NOS1 mRNA
from kidney may start with yet another alternative first
exon. We thus performed rapid amplification of cDNA
ends (59-RACE) with cDNA from kidney and, for compar-
ison, from cerebellum, brain, and skeletal muscle to find
potentially new tissue-specific first exons for rat.
The main 59 ends obtained are depicted in Figure 4.
Messenger RNA starting with a first exon called B1 is
present in nearly all mRNAs tested (brain, cerebellum,
skeletal muscle, kidney, testis, adrenal medulla). This exon
closely resembles the human exon 591. A larger first exon
(C1, 380 bp) is expressed almost exclusively in cerebellum
and comprises sequences homologous to both human ex-
ons, 591, and 592, as well as the postulated short intervening
sequence. Most remarkably, a new kidney-specific first exon
(termed K1, 161 bp) also was found. This is located about
16-kb upstream from exon 2. Of even greater potential
relevance are variants of mRNAs starting with exons K1 or
B1 in which exon 2 was absent. As exon 2 contains the
translation start site, translation of the mRNAs without
exon 2 starts in the corresponding first exons, giving rise to
a shortened NOS1 protein. The first exons K1 and B1
contribute five and seven amino acids, respectively, trans-
lated from alternative translation start sites, but 237 N-
terminal amino acids, normally encoded by exon 2, are
missing in these variants. The missing N-terminal portion
contains a PDZ domain (GLGF motif) and is responsible
for binding of NOS1 to postsynaptic membrane-associated
proteins PSD-93 and PSD-95 in brain or to the sarcolem-
mal dystrophin/synthrophin complex in skeletal muscle
[28]. In renal NOS1 mRNA, the variant that lacks exon 2 (b
form; Fig. 4) is the major species and outnumbers the a
form that contains exon 2 [32]. However, specific antibody
targeted to the translation product that is encoded by exon
2 shows a significant signal in MD. It is thus likely that the
MD contains the a form of NOS1, whereas the cellular
location of the b form in the kidney is not evident at
present. The mRNAs for a and b forms starting with the
same first exon are transcribed from the same promoter.
Nevertheless, these mRNAs differ in their 59 untranslated
region, and their translation may, therefore, be regulated
independently in different cell types.
Fig. 2. In situ hybridization of the juxtaglomerular portion of thick
ascending limb (TAL) in rat with nitric oxide synthase type 1 (NOS1)
antisense probe, digoxigenin-phosphatase labeling. Cells of the macula
densa (MD) are selectively positive for NOS1 mRNA (collaboration with
M. Bostanjoglo). Magnification 3300.
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Effects of NO at the JGA
Nitric oxide released chronically from the MD could
modulate TGF in response to increased tubular [NaCl] [24,
25] either by counteracting vasoconstrictors, by reducing
MD transport, or by interacting with local prostaglandin
synthesis and may also adjust renin production. Both
stimulatory [19] and inhibitory effects [29] of NO on renin
release have been reported, but there is increasing evidence
that decreased luminal [NaCl] at the MD or unilateral
stenosis of the renal artery produce coordinate changes in
NOS1 synthesis and renin production [19, 26, 27]. These
results, however, do not address the question of whether
NO from the MD directly influences the glomerular arte-
rioles or whether the signal primarily reaches the EGM
where it could be transformed to a secondary stimulus,
which, in turn, could influence further the vascular cells. To
address this issue, we employed immunohistochemistry
using antibodies to nitrotyrosin. High amounts of NO
released into the vascular wall have previously been shown
to cause nitration of protein tyrosin [30]. Experimental reno-
vascular hypertension, which leads to maximal activation of
MD NOS1 activity [26], also induces selective protein
nitration in the EGM in the stenotic kidney [31]. NO under
chronic stimulatory conditions therefore reaches the EGM;
with its broad impact on biological functions, a local effect
of NO in the EGM could be generated, which, in turn,
could be transmitted to the glomerular vasculature.
Future studies addressing the role of NO at the JGA will
have to identify both intracellular events governing MD
NOS1 activation and to clarify potential intermediate signal-
ing pathways between MD and the glomerular vasculature.
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APPENDIX
Abbreviations used in article are: EGM, extraglomerular mesangium;
GFR, glomerular filtration rate; JGA, juxtaglomerular apparatus; MD,
macula densa; NKCC2, Na1-2Cl2-K1 cotransporter; NO, nitric oxide;
NOS, nitric oxide synthase; TAL, thick ascending limb; TGF, tubuloglo-
merular feedback; TSC, thiazide-sensitive Na1-Cl2 cotransporter.
Fig. 3. Hypothetical pathways and effects for nitric oxide (NO) at the
juxtaglomerular apparatus. NO in macula densa (MD) is synthesized
from NOS1 and released to the vascular pole of the glomerulus. In the
extraglomerular mesangium (EGM), evidence for nitration of protein
tyrosines has been shown [31]. NO may trigger the release of cGMP in
vascular cells that contain soluble guanylyl cyclase (sGC). In granular cells
of the afferent arteriole (AA), NO may influence renin release and/or
synthesis (renin protein is represented by hatched bars). Apart from
epithelial NO release, endothelial nitric oxide synthase type 3 (NOS3)
produces NO that may reach the vascular wall upon hemodynamic stimuli.
Fig. 4. Schematic representation of the 5* end of the nitric oxide synthase
type 1 (NOS1) gene and the 5* ends of the alternatively spliced NOS1
mRNAs. Exons are represented by boxes and are drawn to scale; introns
are indicated by a thin line and shortened. The three first tissue-specific
exons C1, B1, and K1 are distinguished by different patterns; they are all
noncoding exons. The untranslated region continues in exon 2 (white box);
coding regions are black. The distances (kb) between exons B1 and K1 and
between exons 2 and 3 are indicated. In brain and kidney, mRNA variants
are found with (a) and without (b) exon 2 (coding for a PDZ domain).
Abbreviations are: C, cerebellum; B, brain; K, kidney.
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